strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide

Names

[ CAS No. ]:
914613-86-8

[ Name ]:
strontium,5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide

[Synonym ]:
1H-Benzimidazole,5-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-,strontium salt
(-)-5-Methoxy-2-((S)-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzimidazole strontium salt
Esomeprazole strontium anhydrous
1H-Benzimidazole,6-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-,strontium salt (2:1)
Fm0F67 anhydrous
UNII-SCC2RK476A

Biological Activity

[Description]:

Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

[Related Catalog]:

Research Areas >> Cancer
Research Areas >> Endocrinology
Research Areas >> Inflammation/Immunology
Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump

[In Vitro]

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) hemistrontium treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1]. Cell Viability Assay[1] Cell Line: MDA-MB-468 cells Concentration: 25 µM, 50 µM, 75 µM, 100 µM Incubation Time: 20 hours Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

[In Vivo]

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) hemistrontium treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis[2]. Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2] Dosage: 30 mg/kg, 300 mg/kg Administration: Oral gavage; daily; for 19 or 11 days Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

[References]

[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.

[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.

[3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.

Chemical & Physical Properties

[ Molecular Formula ]:
C34H36N6O6S2Sr

[ Molecular Weight ]:
776.43600

[ Exact Mass ]:
776.11900

[ PSA ]:
186.82000

[ LogP ]:
6.78900

Related Compounds